Trial Profile

Phase 3 study of Cosibelimab in patients with advanced cutaneous squamous cell carcinoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cosibelimab (Primary)
Indications Skin cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Sponsors Fortress Biotech

Most Recent Events

16 Sep 2024 According to Checkpoint Therapeutics Media Release,data from the study were presented at European Society for Medical Oncology (ESMO) Congress 2024 which is taking place in Barcelona, Spain, from September 13 to 17, 2024.
16 Sep 2024 Results presented in the Checkpoint Therapeutics Media Release.
03 Sep 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com